Introduction: The presence of Y-chromosomal material in females with Turner syndrome (TS) is a well-established risk factor for developing gonadoblastoma and malignant transformations thereof. However, these events are rarely seen in TS patients with no Y-chromosomal material. Thus, it is the current understanding that parts of the Y-chromosome are essential for the malignant transformation of gonadoblastoma in the dysgenetic gonad. Methods: We report a case of a TS female with an apparent 46,X,idic(Xq) karyotype, who was diagnosed with a metastatic dysgerminoma. Whole exome sequencing of the tumor and blood, along with RNA sequencing of the tumor, was performed to comprehensively search for cryptic Y-chromosomal material and pathogenic variants. Results: No Y-chromosomal material was detected in either tumor or blood. Whole exome-sequencing of DNA and RNA revealed a pathogenic somatic gain-of-function mutation in KIT and a pathogenic missense mutation in MTOR. The patient underwent total hysterectomy with bilateral salpingo-oophorectomy, followed by adjuvant chemotherapy. Unfortunately, she died due to chemotherapy-induced pneumonitis 7 months after the initial diagnosis. Conclusion: Females with TS can develop metastatic dysgerminoma even in the absence of Y-chromosomal material. This questions the current understanding of Y-chromosomal material being essential for the malignant transformation of a gonadoblastoma in the dysgenetic gonad.

1.
Stochholm
K
,
Juul
S
,
Juel
K
,
Naeraa
RW
,
Gravholt
CH
.
Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome
.
J Clin Endocrinol Metab
.
2006
;
91
(
10
):
3897
902
. .
2.
Cameron-Pimblett
A
,
La Rosa
C
,
King
TFJ
,
Davies
MC
,
Conway
GS
.
The Turner syndrome life course project: karyotype-phenotype analyses across the lifespan
.
Clin Endocrinol
.
2017
;
87
(
5
):
532
8
. .
3.
Berglund
A
,
Viuff
MH
,
Skakkebæk
A
,
Chang
S
,
Stochholm
K
,
Gravholt
CH
.
Changes in the cohort composition of turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
16
. .
4.
Knauer-Fischer
S
,
Besikoglu
B
,
Inta
I
,
Kneppo
C
,
Vogt
PH
,
Bettendorf
M
.
Analyses of Gonadoblastoma Y (GBY)-locus and of Y centromere in Turner syndrome patients
.
Exp Clin Endocrinol Diabetes
.
2015
;
123
(
1
):
61
5
. .
5.
Gravholt
CH
,
Fedder
J
,
Naeraa
RW
,
Müller
J
.
Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study
.
J Clin Endocrinol Metab
.
2000
;
85
(
9
):
3199
202
. .
6.
Cortés-Gutiérrez
EI
,
Herrera-Bartolo
R
,
Dávila-Rodríguez
MI
,
Palacios-Saucedo
GC
,
Vargas-Villarreal
J
,
Romero-Villarreal
JB
.
Molecular detection of cryptic Y-chromosomal material in patients with Turner syndrome
.
Oncol Rep
.
2012
;
28
(
4
):
1205
10
. .
7.
Sallai
A
,
Sólyom
J
,
Dobos
M
,
Szabó
J
,
Halász
Z
,
Ságodi
L
, et al
.
Y-chromosome markers in Turner syndrome: screening of 130 patients
.
J Endocrinol Invest
.
2010
;
33
(
4
):
222
7
. .
8.
Kwon
A
,
Hyun
SE
,
Jung
MK
,
Chae
HW
,
Lee
WJ
,
Kim
TH
, et al
.
Risk of gonadoblastoma development in patients with turner syndrome with cryptic Y chromosome material
.
Horm Cancer
.
2017
;
8
(
3
):
166
73
. .
9.
Roth
LM
,
Cheng
L
.
Gonadoblastoma: origin and outcome
.
Hum Pathol
.
2020
;
100
:
47
53
. .
10.
Karila
D
,
Donadille
B
,
Léger
J
,
Bouvattier
C
,
Bachelot
A
,
Kerlan
V
, et al
.
Prevalence and characteristics of gonadoblastoma in a retrospective multi-center study with follow-up investigations of 70 patients with Turner syndrome and a 45,X/46,XY karyotype
.
Eur J Endocrinol
.
2022
;
187
(
6
):
873
81
. .
11.
Mazzanti
L
,
Cicognani
A
,
Baldazzi
L
,
Bergamaschi
R
,
Scarano
E
,
Strocchi
S
, et al
.
Gonadoblastoma in Turner syndrome and Y-chromosome-derived material
.
Am J Med Genet A
.
2005
;
135
(
2
):
150
4
. .
12.
Cools
M
,
Drop
SL
,
Wolffenbuttel
KP
,
Oosterhuis
JW
,
Looijenga
LH
.
Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers
.
Endocr Rev
.
2006
;
27
(
5
):
468
84
. .
13.
Cools
M
,
Pleskacova
J
,
Stoop
H
,
Hoebeke
P
,
Van Laecke
E
,
Drop
SL
, et al
.
Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism
.
J Clin Endocrinol Metab
.
2011
;
96
(
7
):
E1171
80
. .
14.
Dabrowski
E
,
Johnson
EK
,
Patel
V
,
Hsu
Y
,
Davis
S
,
Goetsch
AL
, et al
.
Turner syndrome with Y chromosome: spontaneous thelarche, menarche, and risk of malignancy
.
J Pediatr Adolesc Gynecol
.
2020
;
33
(
1
):
10
4
. .
15.
Schoemaker
MJ
,
Swerdlow
AJ
,
Higgins
CD
,
Wright
AF
,
Jacobs
PA
;
UK Clinical Cytogenetics Group
.
Cancer incidence in women with Turner syndrome in Great Britain: a National Cohort Study
.
Lancet Oncol
.
2008
;
9
(
3
):
239
46
. .
16.
Gravholt
CH
,
Andersen
NH
,
Conway
GS
,
Dekkers
OM
,
Geffner
ME
,
Klein
KO
, et al
.
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
.
Eur J Endocrinol
.
2017
;
177
(
3
):
G1
70
. .
17.
Silva-Grecco
RL
,
Trovó-Marqui
AB
,
Sousa
TA
,
Croce
LD
,
Balarin
MA
.
Identification of Y-chromosome sequences in turner syndrome
.
Indian J Pediatr
.
2016
;
83
(
5
):
405
9
. .
18.
Bianco
B
,
Lipay
MV
,
Melaragno
MI
,
Guedes
AD
,
Verreschi
IT
.
Detection of hidden Y mosaicism in Turner’s syndrome: importance in the prevention of gonadoblastoma
.
J Pediatr Endocrinol Metab
.
2006
;
19
(
9
):
1113
7
. .
19.
Mittal
S
,
Weaver
J
,
Aghababian
A
,
Edwins
R
,
Godlewski
K
,
Fischer
K
, et al
.
Deferring gonadectomy in patients with turner syndrome with a genetic Y component is not a safe practice
.
J Pediatr Urol
.
2023
;
19
(
3
):
294.e1
5
. .
20.
Graff
A
,
Donadille
B
,
Morel
H
,
Villy
MC
,
Bourcigaux
N
,
Vatier
C
, et al
.
Added value of buccal cell FISH analysis in the diagnosis and management of Turner syndrome
.
Hum Reprod
.
2020
;
35
(
10
):
2391
8
. .
21.
Viuff
MH
,
Stochholm
K
,
Lin
A
,
Berglund
A
,
Juul
S
,
Gravholt
CH
.
Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy
.
Eur J Endocrinol
.
2021
;
184
(
1
):
79
88
. .
22.
Swerdlow
AJ
,
Hermon
C
,
Jacobs
PA
,
Alberman
E
,
Beral
V
,
Daker
M
, et al
.
Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study
.
Ann Hum Genet
.
2001
;
65
(
Pt 2
):
177
88
. .
23.
Ji
J
,
Zöller
B
,
Sundquist
J
,
Sundquist
K
.
Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study
.
Int J Cancer
.
2016
;
139
(
4
):
754
8
. .
24.
Song
S
. Dysgerminoma Pathologyoutlines.com website2023. Available from: https://www.pathologyoutlines.com/topic/ovarytumordysgerminoma.html.
25.
Li
H
.
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
.
2013
. arXiv pre-print server.
26.
Kim
S
,
Scheffler
K
,
Halpern
AL
,
Bekritsky
MA
,
Noh
E
,
Källberg
M
, et al
.
Strelka2: fast and accurate calling of germline and somatic variants
.
Nat Methods
.
2018
;
15
(
8
):
591
4
. .
27.
Rosenthal
R
,
McGranahan
N
,
Herrero
J
,
Taylor
BS
,
Swanton
C
.
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
.
Genome Biol
.
2016
;
17
(
1
):
31
. .
28.
Rausch
T
,
Zichner
T
,
Schlattl
A
,
Stütz
AM
,
Benes
V
,
Korbel
JO
.
DELLY: structural variant discovery by integrated paired-end and split-read analysis
.
Bioinformatics
.
2012
;
28
(
18
):
i333
9
. .
29.
Wala
JA
,
Bandopadhayay
P
,
Greenwald
NF
,
O’Rourke
R
,
Sharpe
T
,
Stewart
C
, et al
.
SvABA: genome-wide detection of structural variants and indels by local assembly
.
Genome Res
.
2018
;
28
(
4
):
581
91
. .
30.
Dobin
A
,
Davis
CA
,
Schlesinger
F
,
Drenkow
J
,
Zaleski
C
,
Jha
S
, et al
.
STAR: ultrafast universal RNA-seq aligner
.
Bioinformatics
.
2013
;
29
(
1
):
15
21
. .
31.
Haas
BJ
,
Dobin
A
,
Li
B
,
Stransky
N
,
Pochet
N
,
Regev
A
.
Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods
.
Genome Biol
.
2019
;
20
(
1
):
213
. .
32.
Uhrig
S
,
Ellermann
J
,
Walther
T
,
Burkhardt
P
,
Fröhlich
M
,
Hutter
B
, et al
.
Accurate and efficient detection of gene fusions from RNA sequencing data
.
Genome Res
.
2021
;
31
(
3
):
448
60
. .
33.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
, et al
.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
.
Genet Med
.
2015
;
17
(
5
):
405
24
. .
34.
Talevich
E
,
Shain
AH
,
Botton
T
,
Bastian
BC
.
CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing
.
PLoS Comput Biol
.
2016
;
12
(
4
):
e1004873
. .
35.
Niu
B
,
Ye
K
,
Zhang
Q
,
Lu
C
,
Xie
M
,
McLellan
MD
, et al
.
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
.
Bioinformatics
.
2014
;
30
(
7
):
1015
6
. .
36.
Gravholt
CH
,
Dollerup
OL
,
Duval
L
,
Mejlgaard
E
,
Stribolt
K
,
Vang
S
, et al
.
A rare case of embryonal carcinoma in a patient with turner syndrome without Y chromosomal material but mutations in KIT, AKT1, and ZNF358 demonstrated using exome sequencing
.
Sex Dev
.
2017
;
11
(
5–6
):
262
8
. .
37.
Gawrychowska
A
,
Iżycka-Świeszewska
E
,
Lipska-Ziętkiewicz
BS
,
Kuleszo
D
,
Bautembach-Minkowska
J
,
Łosin
M
, et al
.
Dysgerminoma with a somatic exon 17 KIT mutation and SHH pathway activation in a girl with turner syndrome
.
Diagnostics
.
2020
;
10
(
12
):
1067
. .
38.
Pierga
JY
,
Giacchetti
S
,
Vilain
E
,
Extra
JM
,
Brice
P
,
Espie
M
, et al
.
Dysgerminoma in a pure 45,X Turner syndrome: report of a case and review of the literature
.
Gynecol Oncol
.
1994
;
55
(
3 Pt 1
):
459
64
. .
39.
Soh
LT
,
Ang
PT
,
Lim-Tan
SK
.
Embryonal carcinoma arising in Turner’s syndrome
.
Ann Acad Med Singap
.
1992
;
21
(
3
):
386
9
.
40.
Sinisi
AA
,
Perrone
L
,
Quarto
C
,
Barone
M
,
Bellastella
A
,
Faggiano
M
.
Dysgerminoma in 45,X Turner syndrome: report of a case
.
Clin Endocrinol
.
1988
;
28
(
2
):
187
93
. .
41.
Cheng
L
,
Roth
LM
,
Zhang
S
,
Wang
M
,
Morton
MJ
,
Zheng
W
, et al
.
KIT gene mutation and amplification in dysgerminoma of the ovary
.
Cancer
.
2011
;
117
(
10
):
2096
103
. .
42.
Kemmer
K
,
Corless
CL
,
Fletcher
JA
,
McGreevey
L
,
Haley
A
,
Griffith
D
, et al
.
KIT mutations are common in testicular seminomas
.
Am J Pathol
.
2004
;
164
(
1
):
305
13
. .
43.
Wang
L
,
Yamaguchi
S
,
Burstein
MD
,
Terashima
K
,
Chang
K
,
Ng
HK
, et al
.
Novel somatic and germline mutations in intracranial germ cell tumours
.
Nature
.
2014
;
511
(
7508
):
241
5
. .
44.
Corless
CL
,
Barnett
CM
,
Heinrich
MC
.
Gastrointestinal stromal tumours: origin and molecular oncology
.
Nat Rev Cancer
.
2011
;
11
(
12
):
865
78
. .
45.
Hoei-Hansen
CE
,
Kraggerud
SM
,
Abeler
VM
,
Kaern
J
,
Rajpert-De Meyts
E
,
Lothe
RA
.
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
.
Mol Cancer
.
2007
;
6
:
12
. .
46.
Hersmus
R
,
Stoop
H
,
van de Geijn
GJ
,
Eini
R
,
Biermann
K
,
Oosterhuis
JW
, et al
.
Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas
.
PLoS One
.
2012
;
7
(
8
):
e43952
. .
47.
Klug
LR
,
Khosroyani
HM
,
Kent
JD
,
Heinrich
MC
.
New treatment strategies for advanced-stage gastrointestinal stromal tumours
.
Nat Rev Clin Oncol
.
2022
;
19
(
5
):
328
41
. .
48.
Evans
EK
,
Gardino
AK
,
Kim
JL
,
Hodous
BL
,
Shutes
A
,
Davis
A
, et al
.
A precision therapy against cancers driven by KIT/PDGFRA mutations
.
Sci Transl Med
.
2017
;
9
(
414
):
eaao1690
. .
49.
Gajiwala
KS
,
Wu
JC
,
Christensen
J
,
Deshmukh
GD
,
Diehl
W
,
DiNitto
JP
, et al
.
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
.
Proc Natl Acad Sci U S A
.
2009
;
106
(
5
):
1542
7
. .
50.
Vega-Ruiz
A
,
Cortes
JE
,
Sever
M
,
Manshouri
T
,
Quintás-Cardama
A
,
Luthra
R
, et al
.
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
.
Leuk Res
.
2009
;
33
(
11
):
1481
4
. .
51.
Zou
Z
,
Tao
T
,
Li
H
,
Zhu
X
.
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
.
Cell Biosci
.
2020
;
10
:
31
. .
52.
Amirnasr
A
,
Sleijfer
S
,
Wiemer
EAC
.
Non-coding RNAs, a novel paradigm for the management of gastrointestinal stromal tumors
.
Int J Mol Sci
.
2020
;
21
(
18
):
6975
. .
53.
Grabiner
BC
,
Nardi
V
,
Birsoy
K
,
Possemato
R
,
Shen
K
,
Sinha
S
, et al
.
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity
.
Cancer Discov
.
2014
;
4
(
5
):
554
63
. .
54.
Zhang
Y
,
Kwok-Shing Ng
P
,
Kucherlapati
M
,
Chen
F
,
Liu
Y
,
Tsang
YH
, et al
.
A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations
.
Cancer Cell
.
2017
;
31
(
6
):
820
32.e3
. .
55.
Lim
JS
,
Kim
WI
,
Kang
HC
,
Kim
SH
,
Park
AH
,
Park
EK
, et al
.
Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy
.
Nat Med
.
2015
;
21
(
4
):
395
400
. .
56.
Hersmus
R
,
van Bever
Y
,
Wolffenbuttel
KP
,
Biermann
K
,
Cools
M
,
Looijenga
LH
.
The biology of germ cell tumors in disorders of sex development
.
Clin Genet
.
2017
;
91
(
2
):
292
301
. .
57.
Tsuchiya
K
,
Reijo
R
,
Page
DC
,
Disteche
CM
.
Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome
.
Am J Hum Genet
.
1995
;
57
(
6
):
1400
7
.
58.
Tian
Q
,
Frierson
HF
Jr
,
Krystal
GW
,
Moskaluk
CA
.
Activating c-kit gene mutations in human germ cell tumors
.
Am J Pathol
.
1999
;
154
(
6
):
1643
7
. .
59.
Viuff
M
,
Skakkebæk
A
,
Johannsen
EB
,
Chang
S
,
Pedersen
SB
,
Lauritsen
KM
, et al
.
X chromosome dosage and the genetic impact across human tissues
.
Genome Med
.
2023
;
15
(
1
):
21
. .
You do not currently have access to this content.